2015 American Transplant Congress
Third Party Mesenchymal Stromal Cell Infusion in Kidney Transplant Recipient: 6-Month Safety Interim Analysis
Back-groundMesenchymal stromal cell (MSC) have immunomodulating properties and could be used as immunosuppressive agents.We report the 6-month safety results for the 5 first patients treated…2015 American Transplant Congress
Pharmacogenomic Predictors of Acute Rejection in Kidney Transplant Recipients Identified Using a DNA Biobank Linked to Electronic Medical Records
Purpose: Risk for acute rejection (AR) complicating transplant immunosuppression may be affected by frequent variants in pharmacogenes. Using a DNA biobank linked to electronic medical…2015 American Transplant Congress
Interference of Therapeutic Antibodies Used in Desensitization Protocols On Lymphocytotoxicity Crossmatch Results
Background: Therapeutic antibodies used to desensitize patients awaiting a human leukocyte antigen (HLA) or ABO-mismatched graft are suspected to interfere with the lymphocytotoxicity crossmatch (LCT-XM)…2015 American Transplant Congress
CMV prevalence in Mauritian and Indonesian Cynomolgus Macaques: Significance in Transplantation and CMV Disease Models
Despite the finding that most macaques express high serologic titers of anti-CMV antibody, susceptibility to disease appears to be variable post-transplant. This observation led us…2015 American Transplant Congress
Steroid-Free Quadruple Induction Regimen With Basiliximab, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Reduces Incidence of Biopsy-Proven Acute Rejection and Toxicity Profile Compared to the Standard Triple Regimen
Department of Renal Transplantation Surgery, Sapporo Hokuyu Hospital, Sapporo, Japan.
Objectives: Nephrotoxicity of calcineurin inhibitors (CNI) in kidney allografts has been a significant clinical problem even with low exposure regimens. On the other hand, CNI-free…2015 American Transplant Congress
Safety and Efficacy of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…2015 American Transplant Congress
Variables Related to the Development of Donor Specific Antibodies (DSA) Post-Kidney Transplant (KTx): Implications for Late Graft Histology and Survival
1Medicine, Mayo Clinic, Rochester, MN; 2Surgery, Mayo Clinic, Rochester, MN.
Introduction. The incidence of de novo DSA increases post-KTx. DSA is associated to reduced graft survival likely due to chronic antibody mediated rejection (cAMR). However,…2015 American Transplant Congress
Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus
BACKGROUND: CMV infection is associated with inferior long-term kidney transplant outcomes. This study compared the incidence of CMV infection/disease in de novo kidney transplant recipients…2015 American Transplant Congress
IL-21 Regulates Creation of Tertiary Lymphoid Organs in Chronic Allograft Rejection
BACKGROUND: IL-21 is a cytokine expressed almost exclusively by cells of the adaptive immune system. This makes it an attractive target for reducing chronic allograft…2015 American Transplant Congress
Not Only CD28null But Also CD28pos T Cells Contribute to Rejection During Belatacept Treatment
To explain the underlying immunological mechanisms for rejection under belatacept treatment, the phenotypical and functional characteristics of graft infiltrating lymphocytes were studied during rejection under…
- « Previous Page
- 1
- …
- 131
- 132
- 133
- 134
- 135
- …
- 138
- Next Page »